Literature DB >> 19595291

[Bacteriological study of ethmoid specimens from patients with nasal polyposis after ethmoidal surgery].

N Day1, J-L Mainardi, D Malinvaud, P Bonfils.   

Abstract

OBJECTIVE: To compare the bacteriological and clinical findings in ethmoid specimens from patients with nasal polyposis after radical ethmoidal surgery. PATIENTS AND METHODS: From June to November 2008, 60 patients were prospectively included. For each patient, two samples for each ethmoidal cavity were taken. Aerobic and anaerobic bacterial cultures and fungal cultures were processed and the antibiotic susceptibility was evaluated for each isolated bacterial strain.
RESULTS: Pathogenic bacteria were isolated in 48 patients (80%) including predominantly Staphylococcus aureus (60%) or a Gram-negative bacterium. The microorganisms were nearly all susceptible to antibiotics, including the aminoglycosides. No correlation between the presence of pathogenic bacteria and the clinical status of the patients was found.
CONCLUSION: In this study, a great number of patients was colonized with pathogenic bacteria. However, the presence of pathogenic bacteria was not correlated with the clinical status of the patients.

Entities:  

Mesh:

Year:  2009        PMID: 19595291     DOI: 10.1016/j.aorl.2009.06.004

Source DB:  PubMed          Journal:  Ann Otolaryngol Chir Cervicofac        ISSN: 0003-438X


  2 in total

1.  Prospective evaluation of oral corticosteroid as a predictor of postoperative olfactory recovery after functional endoscopic surgery for nasal polyposis.

Authors:  Pauline Rives; Florent Espitalier; Guillaume Michel; Xavier Blanc; Cyrille Fortun; Olivier Malard
Journal:  Eur Arch Otorhinolaryngol       Date:  2019-07-03       Impact factor: 2.503

2.  Validation of anatomical models to study aerosol deposition in human nasal cavities.

Authors:  Sandrine Le Guellec; Deborah Le Pennec; Stephane Gatier; Lara Leclerc; Maria Cabrera; Jeremie Pourchez; Patrice Diot; Gregory Reychler; Laurent Pitance; Marc Durand; François Jamar; Laurent Vecellio
Journal:  Pharm Res       Date:  2013-09-25       Impact factor: 4.200

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.